Home/Kyverna Therapeutics/Cameron Durrant, MD, MBA
CD

Cameron Durrant, MD, MBA

Director

Kyverna Therapeutics

Kyverna Therapeutics Pipeline

DrugIndicationPhase
KYV-101Lupus Nephritis (Systemic Lupus Erythematosus)Phase 1/2
KYV-201Undisclosed autoimmune indicationPreclinical